FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035608017> ?p ?o ?g. }

• W2035608017 endingPage "e0116596" @default.
• W2035608017 startingPage "e0116596" @default.
• W2035608017 abstract "At our institute, a chemoradioselection strategy has been used to select patients for organ preservation on the basis of response to an initial 30-40 Gy concurrent chemoradiotherapy (CCRT). Patients with a favorable response (i.e., chemoradioselected; CRS) have demonstrated better outcomes than those with an unfavorable response (i.e., nonchemoradioselected; N-CRS). Successful targeting of molecules that attenuate the efficacy of chmoradioselection may improve results. Thus, the aim of this study was to evaluate the association of a novel cancer stem cell (CSC) marker, CD44 variant 9 (CD44v9), with cellular refractoriness to chemoradioselection in advanced head and neck squamous cell carcinoma (HNSCC).Through a medical chart search, 102 patients with advanced HNSCC treated with chemoradioselection from 1997 to 2008 were enrolled. According to our algorithm, 30 patients were CRC following induction CCRT and 72 patients were N-CRS. Using the conventional immunohistochemical technique, biopsy specimens and surgically removed tumor specimens were immunostained with the anti-CD44v9 specific antibodies.The intrinsic expression levels of CD44v9 in the biopsy specimens did not correlate with the chemoradioselection and patient survival. However, in N-CRS patients, the CD44v9-positive group demonstrated significantly (P = 0.008) worse prognosis, than the CD44v9-negative group. Multivariate analyses demonstrated that among four candidate factors (T, N, response to CCRT, and CD44v9), CD44v9 positivity (HR: 3.145, 95% CI: 1.235-8.008, P = 0.0163) was significantly correlated with the poor prognosis, along with advanced N stage (HR: 3.525, 95% CI: 1.054-9.060, P = 0.0228). Furthermore, the survival rate of the CD44v9-induced group was significantly (P = 0.04) worse than the CD44v9-non-induced group.CCRT-induced CD44v9-expressing CSCs appear to be a major hurdle to chemoradioselection. CD44v9-targeting seems to be a promising strategy to enhance the efficacy of chemoradioselection and consequent organ preservation and survival." @default.
• W2035608017 created "2016-06-24" @default.
• W2035608017 creator A5005893644 @default.
• W2035608017 creator A5014133183 @default.
• W2035608017 creator A5017789799 @default.
• W2035608017 creator A5018505697 @default.
• W2035608017 creator A5019807558 @default.
• W2035608017 creator A5021568645 @default.
• W2035608017 creator A5027079336 @default.
• W2035608017 creator A5028099461 @default.
• W2035608017 creator A5051120510 @default.
• W2035608017 creator A5057184149 @default.
• W2035608017 creator A5059655909 @default.
• W2035608017 date "2015-03-09" @default.
• W2035608017 modified "2023-09-27" @default.
• W2035608017 title "Induction of CD44 Variant 9-Expressing Cancer Stem Cells Might Attenuate the Efficacy of Chemoradioselection and Worsens the Prognosis of Patients with Advanced Head and Neck Cancer" @default.
• W2035608017 cites W1935589503 @default.
• W2035608017 cites W1969737002 @default.
• W2035608017 cites W1980932672 @default.
• W2035608017 cites W1983970003 @default.
• W2035608017 cites W1990956554 @default.
• W2035608017 cites W1992676863 @default.
• W2035608017 cites W1996591010 @default.
• W2035608017 cites W1997058342 @default.
• W2035608017 cites W2017660309 @default.
• W2035608017 cites W2026820127 @default.
• W2035608017 cites W2041399911 @default.
• W2035608017 cites W2063142791 @default.
• W2035608017 cites W2066586420 @default.
• W2035608017 cites W2069850205 @default.
• W2035608017 cites W2083274861 @default.
• W2035608017 cites W2089586603 @default.
• W2035608017 cites W2098435943 @default.
• W2035608017 cites W2100961085 @default.
• W2035608017 cites W2102834025 @default.
• W2035608017 cites W2106288330 @default.
• W2035608017 cites W2111442242 @default.
• W2035608017 cites W2118758371 @default.
• W2035608017 cites W2120613579 @default.
• W2035608017 cites W2122035130 @default.
• W2035608017 cites W2123308199 @default.
• W2035608017 cites W2136310618 @default.
• W2035608017 cites W2141592118 @default.
• W2035608017 cites W2147704625 @default.
• W2035608017 cites W2166842799 @default.
• W2035608017 cites W2167375127 @default.
• W2035608017 doi "https://doi.org/10.1371/journal.pone.0116596" @default.
• W2035608017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4353624" @default.
• W2035608017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25751671" @default.
• W2035608017 hasPublicationYear "2015" @default.
• W2035608017 type Work @default.
• W2035608017 sameAs 2035608017 @default.
• W2035608017 citedByCount "20" @default.
• W2035608017 countsByYear W20356080172016 @default.
• W2035608017 countsByYear W20356080172017 @default.
• W2035608017 countsByYear W20356080172018 @default.
• W2035608017 countsByYear W20356080172019 @default.
• W2035608017 countsByYear W20356080172020 @default.
• W2035608017 countsByYear W20356080172021 @default.
• W2035608017 crossrefType "journal-article" @default.
• W2035608017 hasAuthorship W2035608017A5005893644 @default.
• W2035608017 hasAuthorship W2035608017A5014133183 @default.
• W2035608017 hasAuthorship W2035608017A5017789799 @default.
• W2035608017 hasAuthorship W2035608017A5018505697 @default.
• W2035608017 hasAuthorship W2035608017A5019807558 @default.
• W2035608017 hasAuthorship W2035608017A5021568645 @default.
• W2035608017 hasAuthorship W2035608017A5027079336 @default.
• W2035608017 hasAuthorship W2035608017A5028099461 @default.
• W2035608017 hasAuthorship W2035608017A5051120510 @default.
• W2035608017 hasAuthorship W2035608017A5057184149 @default.
• W2035608017 hasAuthorship W2035608017A5059655909 @default.
• W2035608017 hasBestOaLocation W20356080171 @default.
• W2035608017 hasConcept C121608353 @default.
• W2035608017 hasConcept C126322002 @default.
• W2035608017 hasConcept C141341695 @default.
• W2035608017 hasConcept C142724271 @default.
• W2035608017 hasConcept C143998085 @default.
• W2035608017 hasConcept C146357865 @default.
• W2035608017 hasConcept C1491633281 @default.
• W2035608017 hasConcept C151730666 @default.
• W2035608017 hasConcept C204232928 @default.
• W2035608017 hasConcept C2775934546 @default.
• W2035608017 hasConcept C2776530083 @default.
• W2035608017 hasConcept C2776833033 @default.
• W2035608017 hasConcept C2778424827 @default.
• W2035608017 hasConcept C2780932548 @default.
• W2035608017 hasConcept C54355233 @default.
• W2035608017 hasConcept C55427017 @default.
• W2035608017 hasConcept C71924100 @default.
• W2035608017 hasConcept C86803240 @default.
• W2035608017 hasConcept C90924648 @default.
• W2035608017 hasConceptScore W2035608017C121608353 @default.
• W2035608017 hasConceptScore W2035608017C126322002 @default.
• W2035608017 hasConceptScore W2035608017C141341695 @default.
• W2035608017 hasConceptScore W2035608017C142724271 @default.
• W2035608017 hasConceptScore W2035608017C143998085 @default.
• W2035608017 hasConceptScore W2035608017C146357865 @default.
• W2035608017 hasConceptScore W2035608017C1491633281 @default.

• next